Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06798948 Sponsor: Li Lab,MD Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Phase 2 Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06798948
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with metabolic-associated fatty liver disease with mild to moderate fatty liver.
  • You are between 18 and 65 years old (any gender).
  • You have not taken any liver-protecting medications in the past 3 months.
  • You are willing to sign a consent form and agree to attend all required visits and follow the trial plan.

Who may not be able to join:

  • You drink a large amount of alcohol each week (more than about 210g of pure alcohol for men, or 140g for women), or you are unable to say how much alcohol you drink.
  • You are currently pregnant, breastfeeding, or planning to become pregnant in the next 3 months.
  • You have a known history of allergies, particularly to any ingredients used in the trial product.
  • You have previously used or are currently using liver-support products containing ingredients such as artichoke, milk thistle, turmeric, or liquorice root.
  • You have another liver or gallbladder condition, such as viral hepatitis, autoimmune liver disease, cirrhosis, or liver scarring, among others.
  • You have been diagnosed with obesity, high blood pressure, or diabetes and are currently taking medication to treat any of these conditions.
  • You have certain specific conditions known to cause fatty liver, such as a long-term need for nutrition through a drip (IV), or certain rare metabolic disorders (confirm with trial site).
  • You have been taking medications long-term that are known to cause liver fat build-up, such as amiodarone, methotrexate, tamoxifen, or steroid medicines.
  • You have a serious heart, stroke-related, or kidney condition.
  • Your weight has changed by more than 5% or you have been losing weight very quickly (more than 1.6kg per week) in the 6 to 8 weeks before the trial starts.
  • You have had a cancer diagnosis in the past 5 years (except for a specific type of minor skin cancer called basal cell carcinoma).
  • You have a history of a weakened immune system, HIV, or AIDS, or you are currently taking medicines that suppress your immune system, or receiving radiotherapy.
  • You have certain ongoing conditions such as asthma, epilepsy, or a thyroid disorder, or are taking medicines to treat these.
  • You have a history of drug abuse.
  • You have taken antibiotics within the past month.
  • You have taken part in another health intervention study in the past 3 months, or received any other treatment outside of this trial during the study.
  • You have other circumstances that researchers feel may make it difficult for you to fully participate, such as frequently changing where you live or work, which could make follow-up difficult (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Songtao Li, Zhejiang Chinese Medical University

Phone: 08615267148306

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Li Lab,MD
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
31 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Magnetic Resonance Imaging proton density fat fraction in hepatic steatosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov